HARP - Harpoon shares slide after early-stage prostate cancer study data fails to impress

Harpoon Therapeutics shares fall ([[HARP]] -21.6%) after interim data from its ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer ((mCRPC)) failed to impress investors.The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts.The data showed only one confirmed case of partial response ((PR)), and treatment duration > 24 weeks was observed in 15 of 74 (20%) patients.The most frequent adverse events were cytokine release syndrome ((CRS)), chills, and pyrexia, with the majority of CRS events occurring with the first dose.Dose Limiting Toxicities ((DLTs)) were observed at doses ranging from 96 to 300ng/kg and did not limit escalation and Maximum Tolerated Dose has not been reached, the company said. The most common reason for study discontinuation was progressive disease; two of 89 (2%) patients discontinued treatment due to treatment-related adverse events.Harpoon shares are up ~26% YTD.#ASCO21

For further details see:

Harpoon shares slide after early-stage prostate cancer study data fails to impress